Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 648 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Torisel (Temsirolimus) Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: Rapamycin, Surgery, Supportive Care; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Cancer
Interventions: Doxil, Bevacizumab, Temsirolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Interventions: sirolimus; Drug
Lead sponsor: Denise Martin Adams; Other
Eligibility: Up to 31 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
Interventions: Sirolimus; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer Metastatic
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more

Conditions: Tuberous Sclerosis Complex, Self-injury, Autism
Interventions: Sirolimus, Everolimus; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 2 Years to 30 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: Temsirolimus, Sorafenib:; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Chicago, Illinois

Conditions: Renal Transplant Recipients
Interventions: ATG, Rituximab, Tacrolimus, Sirolimus, MMF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Sickle Cell Disease
Interventions: Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus; Procedure · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 16 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer
Interventions: n/a- this is an observational study; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Brain and Central Nervous System Tumors
Interventions: GDC-0084, radiation therapy; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HNSCC
Interventions: Bimiralisib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Insulin Resistance
Interventions: Everolimus 0.5 MG once per day, Everolimus 5 MG once per week, Placebo once per day, Placebo once per week; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Interventions: Simvastatin, Sirolimus Oral Product, Everolimus Oral Product; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Severe Aplastic Anemia
Interventions: ATG+Rapamune+cyclosporine, ATG+cyclosporine; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 110 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Interventions: EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane; Drug
Lead sponsor: Ellipses Pharma; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more

Conditions: Hepatocellular Carcinoma
Interventions: sorafenib with temsirolimus; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: San Francisco, California • Chicago, Illinois

Conditions: Type 1 Diabetes (T1D), Islet Transplantation
Interventions: Maintenance Immunosuppressive Treatment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Lymphangioleiomyomatosis
Interventions: Sirolimus, Resveratrol; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 1 Diabetes
Interventions: Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Sirolimus in Treating Patients With Glioblastoma Multiforme

Doxil, Bevacizumab and Temsirolimus Trial

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Rapalogues for Autism Phenotype in TSC: A Feasibility Study

Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Research Study of ATG and Rituximab in Renal Transplantation

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

Everolimus Aging Study

Daily Topical Rapamycin for Vitiligo

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Safety of Simvastatin in LAM and TSC

Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Extended Follow-Up After Islet Transplantation in T1D

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients